Access Pharmaceuticals Announces Positive Top-Line Data From MuGard?...

Met Primary Endpoint of Statistically Significant Reduction in Mouth and Throat Soreness Associated With Oral Mucositis; MuGard Patients Also Had Decreased Severity of Oral Mucositis by WHO Score Met Primary Endpoint of Statistically Significant Reduction in Mouth and Throat Soreness Associated With Oral Mucositis; MuGard Patients Also Had ... (more)

http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Access-Pharmaceuticals-Announces-Positive-Top-Line/ArticleNewsFeed/Article/detail/816900?ref=25